Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos and Cystic Fibrosis Foundation Therapeutics, the non-profit affiliate of the Cystic Fibrosis Foundation, have signed a new collaboration aimed at discovering new treatments for cystic fibrosis, which is worth up to $8.1 million for Galapagos.
Subscribe to our email newsletter
Under the terms of the agreement, Galapagos stands to receive up to $2.4 million in upfront and research fees over the next two years, and up to $5.7 million in success-based milestone payments, should certain clinical development criteria be met.
Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called cystic fibrosis transmembrane conductance regulator (CFTR). To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.
Robert Beall, president and CEO of the Cystic Fibrosis Foundation, said: “By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.”